expect
report open next tuesday novemb
seen solid volum med-tech far organ sale growth
out-performance across coverag univers ortho cardio medsurg
repres posit read-through result
forecast assum modest organ beat current coupl
modest upsid told forecast revenu come
report organ step street
organ less upsid potenti vs given
harder rel comp expect mostli in-lin
consensu ep wouldnt surpris see
cent upsid similar past quarter alreadi saw
manag hold top-lin organ growth steadi despit out-performance
given back-end load year wouldnt expect guidanc move
higher beat vs today similarli think rais
ep limit out-performance quarter
expect organ sale growth guidanc could move
beat vs street rememb manag alreadi chose
hold guidanc steadi despit organ beat kick year
beat would put solidli in-lin growth year
think decis repres manag conservat anyth
els model point toward readili achiev
growth acceler
despit easier comp continu ramp new
product short believ ampl runway beat rais
similar expect manag rais ep size
quarterli beat given expect top-lin beat medtron
consist perform past sever quarter think
good chanc sever cent oper driven upsid weve
alreadi seen number large-cap player rais expect fx
headwind given currenc move sinc euro today
vs report august someth could
impact though dont believ preclud rais
look quarter high-level see upsid driven apv
spine brain therapi surgic innov
off-set lower expect crhf cgm
told get us revenu report
organ roughli consensu organ
back headwind fx benefit
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
past year weve seen signific turnaround
perform manag return
consist exceed expect importantli
materi improv gener
stick point mani investor next month
believ medtron grow least plu see
number underappreci data present
transform new product launch appear
fulli appreci street conserv leav
potenti catalyst see come upsid vs
forecast manag set appropri
conserv bar long-rang top-lin earn
progress june analyst day see meaning
upsid street estim year ahead potenti
multipl expans sustain execut
dec price target share
base price-to-earnings multipl slight discount
large-cap med-tech peer set appli calendar ep
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
dive deeper see cardiac vascular group cvg grow
organ in-lin street one hand
conserv heart failur busi model
factor organ declin reflect lower high-pow
assumpt given continu share loss icd crt-d
on-going competit headwind lvad busi lead us come
partial off-set bullish outlook power
given modest growth pacemak elsewher bullish
aortic peripher apv beat despit expect headwind
dcb franchis final modestli coronari structur
heart out-performance coronari off-set lower expect structur
heart specif ou tavr given standout quarter
edward howev wouldnt surpris see upsid tavr
move restor therapi rtg forecast organ growth
drive sale street see upsid
come brain therapi follow spine pain
slightli street factor declin organ
abl return growth quarter
said large-cap player space market
forecast declin us
diabet forecast growth organ
consensu rememb manag expect off-year
franchis given on-going competit pressur difficult comp us
even stronger expect quarter alreadi releas earlier
earn season surpris see weaker us diabet number
off-set better growth on-going launch
finish minim invas therapi mitg forecast organ
growth revenu consensu see
surgic innov grow organ come
coupl modest beat respiratori gastrointestin renal grow
organ overal busi see modest benefit full
lap sterigen steril plant disrupt someth impact
extent safeti stock deplet
 broadli in-lin street ep see
gross margin come street y/i
reflect increment headwind fx oper expens line
fulli in-lin step higher sg vs
told get us oper margin vs street
 roughli in-lin expens vs
step higher incom vs step lower interest
expens vs told lead us cash ep
quarter in-lin street
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat-and-rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least plu see number underappreci data
present transform new product launch appear fulli
appreci street conserv leav potenti catalyst
see come upsid vs forecast manag set appropri
conserv bar long-rang top-lin earn progress june
analyst day see meaning upsid street estim year ahead
potenti multipl expans sustain execut
dec price target share base price-to-earnings multipl
slight discount large-cap med-tech peer set appli calendar
ep estim see appropri given compani in-lin outlook
long-term off-set modest headwind near-term
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower-than-anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
